CD19 and non-Hodgkin lymphoma: CD19-directed CAR-T cells are now part of the therapeutic options for patients with R/R NHL including MCL, offering hope for curative responses thanks to a reprogramed T lymphocyte specificity and function able to target CD19 [93,94] (Table 3).